Laboratory of Molecular and Cellular Therapy, Department of Biomedical Sciences, Vrije Universiteit Brussel, Jette, Belgium.
Front Immunol. 2018 Sep 11;9:2052. doi: 10.3389/fimmu.2018.02052. eCollection 2018.
Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor activity. Consequently, DCs have been explored as cellular vaccines in cancer immunotherapy. To that end, DCs are modified with tumor antigens to enable presentation of antigen-derived peptides to CTLs. In this review we discuss the use of viral vectors for modification of DCs, focusing on their clinical applications as anticancer vaccines. Among the viral vectors discussed are those derived from viruses belonging to the families of the , and . We will further shed light on how the combination of viral vector-based vaccination with T-cell supporting strategies will bring this strategy to the next level.
树突状细胞 (DCs) 被认为是具有高效抗原呈递能力的细胞，能够刺激具有抗肿瘤活性的细胞毒性 T 淋巴细胞 (CTL) 反应。因此，DC 已被探索作为癌症免疫疗法中的细胞疫苗。为此，用肿瘤抗原修饰 DC，以使其能够向 CTL 呈递抗原衍生的肽。在本综述中，我们讨论了病毒载体在修饰 DC 中的应用，重点介绍了它们作为抗癌疫苗的临床应用。所讨论的病毒载体包括属于 、 和 家族的病毒衍生的载体。我们将进一步阐明如何将基于病毒载体的疫苗接种与 T 细胞支持策略相结合，将这一策略提升到一个新的水平。
Zotero 插件